Somatic mutations or deletions in PTEN, a critical tumor suppressor, are frequently observed in breast tumors and disrupt the phosphatase activity of PTEN, leading to unchecked activation of the PI3K/AKT/mTOR pathway. Here, PTEN is linked to neoplasm.